GlassScriptPhysician profile
Vicente Vazquez
NPI 1861978371
$7,532.62
in general payments reported to CMS, 2019-2025
40 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $2,072 · 2023: $1,675 · 2024: $1,219 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.96 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $552.32 | 2022-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $546.34 | 2021-2025 | |
| Novo Nordisk INC | $496.85 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.65 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $467.25 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.11 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $396.61 | 2022-2025 | |
| Amgen INC. | $388.31 | 2021-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $287.68 | 2022-2025 | Veozah, Myrbetriq |
| Ucb, INC. | $259.99 | 2021-2022 | |
| Corcept Therapeutics | $244.96 | 2024-2025 | Korlym |
| Lilly USA, LLC | $239.15 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $190.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $179.57 | 2021-2025 | Trelegy Ellipta, Arexvy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $165.69 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.42 | 2024-2025 | Caplyta |
| Abbott Laboratories | $143.30 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $143.05 | 2022 | |
| Almatica Pharma LLC | $122.60 | 2023-2025 | Loreev Xr, Teriparatide, Gralise |
| Sumitomo Pharma America, INC. | $114.86 | 2023-2025 | Gemtesa |
| Biogen, INC. | $107.84 | 2021-2025 | Leqembi |
| Alpha Cognition USA, INC. | $97.39 | 2025 | Zunveyl |
| Axsome Therapeutics, INC. | $86.04 | 2025 | Symbravo |
| Avanir Pharmaceuticals, INC. | $73.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.65 | 2021-2023 | Eliquis |
| Scilex Pharmaceuticals INC. | $53.00 | 2024-2025 | |
| Eisai INC. | $41.62 | 2021-2025 | |
| Viatris Specialty LLC | $39.63 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $38.57 | 2021 | |
| Dexcom, INC. | $36.30 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $31.88 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.20 | 2023 | |
| Nestle Healthcare Nutrition INC. | $24.15 | 2023 | |
| Cequr Corporation | $24.10 | 2024 | Cequr Simplicity |
| Vivus LLC | $23.34 | 2024 | Qsymia |
| Idorsia Pharmaceuticals US INC | $22.67 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $21.04 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.48 | 2025 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $16.08 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.